NO.01Building↑ 101%
Participants counted19
Heat, past 7 daysPeak 9 · 10d ago
7d agonow
and 44 other sources reporting·44 participants
84
Heat index
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
Over 22,000 attendees and more than 7,400 abstracts, including a record 265 clinical trial abstracts. This section collects on-site analysis across fifteen signal directions, plus late-breaking, clinical-trial and new-drug abstracts.
NO.02Building↑ 28%
daraxonrasib
43 sources · 43 participants
51
NO.03↓ 21%
ivonescimab
49 sources · 49 participants
34
Page 1 No.04–20
Participants · trend · heat index- 04
trastuzumab
31↓ 21%31↓ 21% - 05
nivolumab
30↑ 11%30↑ 11% - 06
adebrelimabBuilding
29↑ 83%29↑ 83% - 07
VS-7375
18↓ 21%18↓ 21% - 08
AACR 2026
10↓ 20%10↓ 20% - 09
durvalumab
2↓ 18%2↓ 18% - 10
atezolizumab
2↓ 20%2↓ 20% - 11
sotorasib
2↓ 22%2↓ 22% - 12
olaparib
1↓ 14%1↓ 14% - 13
TRI-611
0↓ 20%0↓ 20% - 14
FHD-909
0↓ 33%0↓ 33% - 15
tremelimumab
0flat0flat - 16
zanidatamab
0New0New - 17
KRAS
0New0New - 18
#HEALTHLITERACY
0New0New - 19
HER2
0New0New - 20
zoldonrasib
0New0New